Compare ORBS & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORBS | CDXS |
|---|---|---|
| Founded | 1966 | 2002 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | | Major Chemicals |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.0M | 256.3M |
| IPO Year | N/A | 2008 |
| Metric | ORBS | CDXS |
|---|---|---|
| Price | $0.60 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.9M | 796.1K |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $0.57 | $0.96 |
| 52 Week High | $15.96 | $3.87 |
| Indicator | ORBS | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 37.44 | 23.79 |
| Support Level | N/A | $1.10 |
| Resistance Level | $1.23 | $1.86 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 21.37 | 5.33 |
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.